Telehealth Performance - Telehealth revenue increased by 34% for the nine months ended September 30, 2025, compared to the same period in 2024, with total revenue from recurring subscriptions approximately 95%[156]. - Telehealth revenue accounted for 79% of total revenue, increasing by approximately $6.4 million due to higher online sales demand[171]. - Telehealth revenue for the nine months increased by 34%, contributing approximately $41.2 million to the overall revenue growth[177]. Patient Engagement - LifeMD currently treats approximately 311,000 active patient subscribers and has served around 1,293,000 customers since inception[153]. - The GLP-1 Weight Management Program has grown to approximately 82,000 patient subscribers as of September 30, 2025, following its launch in April 2023[161]. - LifeMD's core telehealth brands, including LifeMD and Rex MD, have served over 1.26 million customers collectively, addressing various healthcare needs[161][165]. Financial Performance - Total revenue for the three months ended September 30, 2025, was approximately $60.2 million, a 13% increase from $53.3 million in the same period of 2024[171]. - For the nine months ended September 30, 2025, total revenue was approximately $187.0 million, a 25% increase from $149.3 million in the same period of 2024[177]. - Gross profit increased by 9% to approximately $52.8 million, with gross profit margin decreasing to 88% from 91% year-over-year[173]. Operating Expenses - Operating expenses for the three months ended September 30, 2025, were approximately $54.7 million, a 5% increase from $52.3 million in the prior year[174]. - Operating expenses for the nine months ended September 30, 2025, were approximately $164.9 million, an increase of 11% or approximately $15.8 million compared to $149.1 million for the same period in 2024[180]. - Selling and marketing expenses increased by approximately $10.6 million, or 14%, primarily due to additional initiatives for LifeMD virtual primary care[182]. Net Loss and Cash Flow - The company recorded a net loss of approximately $3.6 million for the three months ended September 30, 2025, compared to a net loss of $4.8 million in the same period of 2024[170]. - Net cash provided by operating activities was approximately $11.6 million for the nine months ended September 30, 2025, compared to approximately $16.4 million for the same period in 2024[184]. - Working capital decreased by approximately $0.5 million during the nine months ended September 30, 2025, with current assets at approximately $41.1 million and current liabilities at approximately $56.7 million[183]. Debt and Financing - The company recorded a loss on debt extinguishment of $1.2 million related to the repayment of the Avenue Facility during the three months ended September 30, 2025[176]. - The Company recorded a $1.2 million loss on debt extinguishment related to the repayment of the Avenue Facility during the nine months ended September 30, 2025[181]. - The Company sold 762,990 shares of common stock under the ATM Sales Agreement during the three months ended September 30, 2025, generating net proceeds of $8.7 million[189]. Future Plans and Developments - The company plans to expand insurance acceptance to over 60 million Medicare beneficiaries nationwide, with access to qualifying services across 49 states[155]. - The company aims to introduce new telehealth product and service offerings to complement its existing treatment areas as part of its long-term growth strategy[154]. - LifeMD's wholly-owned affiliated commercial pharmacy, opened in November 2024, is designed to fill up to 5,000 daily prescriptions, enhancing the integrated care journey[163]. Accounting Standards - FASB issued ASU 2025-06 to simplify accounting for internal-use software costs, effective for annual periods after December 15, 2027[197]. - Capitalization of eligible software development costs begins when management authorizes and commits to funding the project[197]. - The company is evaluating the impact of the new guidance on consolidated financial statements and related disclosures[197].

Financial Performance - Total revenue increased 13% year-over-year to $60.2 million, with telehealth revenue growing 18% to $47.3 million[6] - Adjusted EBITDA rose 20% to $5.1 million, while telehealth adjusted EBITDA increased 30% to $2.9 million[6] - For the fourth quarter of 2025, the company expects revenue in the range of $45 million to $46 million and adjusted EBITDA between $3 million and $4 million[10] - Full year 2025 revenue is projected to be between $192 million and $193 million, reflecting an increase of approximately 24% versus 2024[10] - Total revenues for the nine months ended September 30, 2025, increased to $186.98 million, a 25.3% rise from $149.34 million in the same period of 2024[20] - Gross profit for Q3 2025 was $52.76 million, compared to $48.26 million in Q3 2024, reflecting an increase of 9.3%[20] - The consolidated adjusted EBITDA for the nine months ended September 30, 2025, was $19,796,724, significantly higher than $8,115,725 for the same period in 2024[28] Subscriber Growth - The number of active telehealth subscribers increased 14% to approximately 310,000 at quarter-end[9] - LifeMD's RexMD business added nearly 10,000 net new subscribers in the quarter, returning to growth[3] Debt and Cash Management - LifeMD paid off all outstanding debt during the quarter, significantly strengthening its balance sheet[5] - Cash at the end of Q3 2025 was $23.79 million, down from $37.59 million at the end of Q3 2024[22] - Net cash used in operating activities for Q3 2025 was $(147,137), a significant decrease from $6.20 million provided in Q3 2024[22] Operating Loss and Expenses - Operating loss for Q3 2025 narrowed to $(1.97) million, an improvement from $(4.00) million in Q3 2024[20] - Net loss attributable to LifeMD, Inc. for Q3 2025 was $(3.81) million, compared to $(4.66) million in Q3 2024, showing a reduction of 18.2%[20] - Total expenses for the nine months ended September 30, 2025, were $164.94 million, up from $149.13 million in the same period of 2024[20] Telehealth Performance - Telehealth revenue for Q3 2025 reached $47.28 million, up 17.5% from $40.15 million in Q3 2024[20] - Telehealth operating loss for the three months ended September 30, 2025, was $3,043,374, an improvement from a loss of $3,745,522 in 2024[29] - Telehealth adjusted EBITDA for the nine months ended September 30, 2025, reached $10,494,043, compared to $2,664,501 in 2024[29] WorkSimpli Performance - LifeMD completed the divestiture of its majority ownership in WorkSimpli, transforming into a pure-play virtual care and pharmacy platform[4] - WorkSimpli reported an operating income of $1,074,160 for the three months ended September 30, 2025, a recovery from an operating loss of $250,752 in 2024[30] - WorkSimpli adjusted EBITDA for the nine months ended September 30, 2025, was $9,302,680, up from $5,451,224 in 2024[30] Other Financial Metrics - Gross margin was 88% compared to 91% in the prior-year period, with telehealth gross margin at 86% excluding WorkSimpli[9] - The company incurred litigation costs of $959,802 for the three months ended September 30, 2025, compared to $644,170 in 2024[29] - Stock-based compensation expense for the three months ended September 30, 2025, was $3,198,036, compared to $2,394,235 in 2024[29] - The company reported a foreign exchange loss of $314,960 for the three months ended September 30, 2025[30] - Interest expense (excluding amortization of debt discount) for the nine months ended September 30, 2025, was $1,317,389, compared to $1,266,412 in 2024[28] Strategic Plans - LifeMD plans to enhance its core telehealth business while managing the non-core subsidiary WorkSimpli separately[24]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended June 30, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from _________ to _________ Commission file number: 001-39785 LIFEMD, INC. (Exact name of registrant as specified in its charter) Delaware 76-0238453 (State or other Jurisdict ...

Exhibit 99.1 LifeMD Reports Second Quarter 2025 Results Conference call begins at 4:30 p.m. Eastern time today NEW YORK, August 5, 2025 — LifeMD, Inc. (Nasdaq: LFMD), a leading provider of virtual primary care services, today reported financial results for the three and six months ended June 30, 2025. Management Commentary "The second quarter of 2025 was an extremely productive quarter for LifeMD and the evolution of our telehealth platform," said Justin Schreiber, Chairman and CEO of LifeMD. "Hundreds of t ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended March 31, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from _________ to _________ Commission file number: 001-39785 LIFEMD, INC. (Exact name of registrant as specified in its charter) | | | (State or other Jurisdiction of Incorp ...

LifeMD Reports First Quarter 2025 Results and Raises Full-Year 2025 Guidance Conference call begins at 4:30 p.m. Eastern time today NEW YORK, May 6, 2025 — LifeMD, Inc. (Nasdaq: LFMD), a leading provider of virtual primary care services, today reported financial results for the three months ended March 31, 2025. Management Commentary Exhibit 99.1 Justin Schreiber, Chairman and CEO of LifeMD, said, "LifeMD had an outstanding first quarter that demonstrated the power of our platform, the need for our services ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from __________________________ to __________________________ Commission file number 001-39785 LIFEMD, INC. (Exact name of registrant as specified in its charter) | Del ...

Exhibit 99.1 LifeMD Reports Fourth Quarter 2024 Results ● Consolidated revenue increased 43% to $64.3 million with telehealth revenue up 60%. ● Telehealth active subscribers increased 27% to approximately 275,000 at quarter-end. Full Year Financial Highlights Conference call begins at 4:30 p.m. Eastern time today NEW YORK, March 10, 2025 — LifeMD, Inc. (Nasdaq: LFMD), a leading provider of virtual primary care services, today reported financial results for the three and 12 months ended December 31, 2024. Ma ...

Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended September 30, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from ________ to _________ Commission file number: 001-39785 LIFEMD, INC. (Exact name of registrant as specified in its charter) (State or other Jurisdiction of Incorpora ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended June 30, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from ________ to _________ Commission file number: 001-39785 LIFEMD, INC. (Exact name of registrant as specified in its charter) Delaware 76-0238453 (State or other Jurisdicti ...